Combining ulixertinib (ERK1/2 Inhibitor) with EGFR and BRAF inhibition yields significant efficacy in preclinical BRAFV600E mutant colorectal cancer modelsDeborah Knoerzer,Anupama Reddy,Jessica A. Box,Anna Groover,Brent Kreider,Martin Teresk,Caroline M. EmeryCANCER RESEARCH（2023）引用 0|浏览16暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
